| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1035551114 |
| P356 | DOI | 10.2165/00003495-198427040-00003 |
| P8608 | Fatcat ID | release_65lmytm74zea5paw3oq3qrgje4 |
| P698 | PubMed publication ID | 6327221 |
| P2093 | author name string | M J Eadie | |
| P2860 | cites work | Sequelae after the intravenous injection of three benzodiazepines--diazepam, lorazepam, and flunitrazepam | Q28316862 |
| Stupor Following Administration of Valproic Acid to Patients Receiving Other Antiepileptic Drugs | Q28319205 | ||
| Diphenylhydantoin Sensitivity. A Syndrome Resembling Infectious Mononucleosis with a Morbilliform Rash and Cholestatic Hepatitis | Q28319528 | ||
| Tremor due to sodium valproate | Q28325069 | ||
| The fetal trimethadione syndrome: report of an additional family and further delineation of this syndrome | Q28325493 | ||
| Intravenous phenytoin: Clinical and pharmacokinetic aspects | Q28330095 | ||
| Diphenylhydantoin-induced acute renal failure | Q28331432 | ||
| Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics | Q28335688 | ||
| Serum clonazepam concentrations in children with absence seizures | Q28336526 | ||
| Digoxin-phenytoin interaction | Q28365258 | ||
| Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates | Q28366176 | ||
| Sodium valproate, platelet dysfunction, and bleeding | Q33481528 | ||
| Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically pathologically malignant lymphomas | Q33969972 | ||
| Pharmacokinetics and side-effects of clonazepam and its 7- amino-metabolite in man | Q34151795 | ||
| Drug Interactions During Anticonvulsant Therapy in Childhood: Diphenylhydantoin, Primidone, Phenobarbitone, Clonazepam, Nitrazepam, Carbamazepin and Dipropylacetate | Q34170346 | ||
| Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism. | Q34208762 | ||
| Human pharmacokinetics of nitrazepam: Effect of age and diseases | Q34212765 | ||
| Effects of Phenytoin on Serum y-Glutamyl Transpeptidase Activity | Q72475336 | ||
| The effect of phenobarbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes | Q72505905 | ||
| Epilepsy | Q72540124 | ||
| Interactions between prim done, carbamazepine, and nicotinamide | Q72765756 | ||
| The role of folate deficiency in the development of peripheral neuropathy caused by anticonvulsants | Q72872715 | ||
| The interaction of barbiturates with serum albumin and its possible relation to their disposition and pharmacological actions | Q73536304 | ||
| Phenobarbital: studies of elimination, accumulation, tolerance, and dosage schedules | Q73564415 | ||
| Diphenylhydantoin sensitivity; report of fatal case with hepatitis and exfoliative dermatitis | Q73938395 | ||
| Quantitative studies of the metabolic fate of mephobarbital (N-methyl phenobarbital) | Q73963976 | ||
| The metabolic hydroxylation of phenobarbital | Q73970865 | ||
| Metabolic conversion of primidone (mysoline) to phenobarbital | Q74349568 | ||
| The metabolic conversion of 5, 5-diphenyl hydantoin to 5-(p-hydroxyphenyl)-5-phenyl hydantoin | Q74594017 | ||
| Effects of diphenylhydantoin on synaptic transmission in cat spinal cord and stellate ganglion | Q74660352 | ||
| [ON THE PHARMACOLOGY OF MOGADON, A HYPNOTIC WITH AN UNUSUAL ACTION MECHANISM] | Q77230595 | ||
| PHENOBARBITAL-INDUCED INCREASE IN 6-BETA-HYDROXYCORTISOL EXCRETION: CLUE TO ITS SIGNIFICANCE IN HUMAN URINE | Q78248238 | ||
| DRUG INTERACTIONS IN MAN. I. LOWERING EFFECT OF PHENOBARBITAL ON PLASMA LEVELS OF BISHYDROXYCOUMARIN (DICUMAROL) AND DIPHENYLHYDANTOIN (DILANTIN) | Q78443509 | ||
| Neuropharmacology and neurochemistry of anticonvulsant drugs | Q78619793 | ||
| Exfoliative dermatitis and hepatitis due to phenobarbital | Q80680980 | ||
| Influence of folic acid on blood-phenytoin levels | Q93694688 | ||
| Acute primidone intoxication | Q34219145 | ||
| Cerebrospinal-fluid concentrations of nitrazepam in man. | Q34239485 | ||
| Transfer of nitrazepam across the human placenta | Q34243003 | ||
| Rectal drug administration: clinical pharmacokinetic considerations | Q34246983 | ||
| Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics | Q34270748 | ||
| Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy | Q34271569 | ||
| Antiepileptic Drugs: Biotransformation, Metabolism, and Serum Half-Life | Q34359667 | ||
| Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients | Q34448908 | ||
| Valproic acid and diazepam interaction in vivo | Q34450028 | ||
| Plasma protein binding of phenytoin in the aged: in vivo studies | Q34450124 | ||
| Phenytoin dose adjustment in epileptic patients | Q34451359 | ||
| Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding | Q34451491 | ||
| The effects of age and liver disease on the disposition and elimination of diazepam in adult man | Q34473755 | ||
| Controlled trial of frusemide as an antiepileptic drug in focal epilepsy | Q34515240 | ||
| Effect of phenytoin therapy on thyroid function | Q34515422 | ||
| Factors influencing plasma phenobarbitone levels in epileptic patients | Q34516004 | ||
| The levels of anticonvulsants in breast milk | Q34517631 | ||
| Effects of subjects' sex, and intake of tobacco, alcohol and oral contraceptives on plasma phenytoin levels | Q34517775 | ||
| Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients | Q34517822 | ||
| Modification of phenytoin clearance by valproic acid in normal subjects | Q34518500 | ||
| Diazepam and N-desmethyldiazepam concentrations in saliva, plasma and CSF | Q34518792 | ||
| Comparison of plasma and saliva levels of diazepam | Q34518984 | ||
| Interactions between anticonvulsants | Q34561260 | ||
| Phenytoin-theophylline interaction | Q34715451 | ||
| Pancreatitis during sodium valproate treatment | Q35117150 | ||
| Interactions with Antiepileptic Drugs | Q36493244 | ||
| Chronic Antiepileptic Toxicity: A Review | Q36522161 | ||
| Pathophysiology behind anticonvulsant osteomalacia | Q36614874 | ||
| Treatment of epilepsy with clonazepam and its effect on other anticonvulsants | Q37053391 | ||
| The distribution of plasma phenytoin levels in epileptic patients | Q37070680 | ||
| The Teratogenic Risk of Antiepileptic Drugs | Q38094480 | ||
| Acute Toxicity of Antiepileptic Drugs | Q38094502 | ||
| Metabolic fate of phenobarbital. A quantitative study of p-hydroxyphenobarbital elimination in man | Q39136268 | ||
| Pharmacokinetics of Diazepam in Dogs, Mice and Humans | Q52739703 | ||
| Acute diphenylhydantoin intoxication following halothane anesthesia. | Q52741995 | ||
| Plasma disappearance of transplacentally transferred diphenylhydantoin in the newborn studied by mass fragmentography. | Q53864786 | ||
| Increased Rate of Clearance of Drugs from the Circulation of Alcoholics* | Q54004788 | ||
| Effect of methylphenidate on plasma anticonvulsant levels | Q54033546 | ||
| Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. | Q54054255 | ||
| Intramuscular administration of diphenylhydantoin. Histologic follow-up studies. | Q54065624 | ||
| Diphenylhydantoin and an insulin-secreting islet adenoma. | Q54260776 | ||
| Folate therapy in epilepsy. A controlled study. | Q54293478 | ||
| Effect of diphenylhydantoin on cortisol kinetics in humans | Q54306410 | ||
| Clonazepam--a clinical study of its effectiveness as an anticonvulsant | Q54312115 | ||
| Interaction between Doxycycline and Barbiturates | Q54384492 | ||
| Low plasma-bilirubin in epileptics on phenobarbitone. | Q54432717 | ||
| Effect of diphenylhydantoin on the metabolism of dicoumarol in man. | Q54488007 | ||
| Osteomalacia with Long-term Anticonvulsant Therapy in Epilepsy | Q54732571 | ||
| Altered Calcium Metabolism in Epileptic Children on Anticonvulsants | Q55174462 | ||
| Hyponatraemia during carbamazepine treatment. | Q55410979 | ||
| Nitrazepam in myoclonic epilepsies | Q57605674 | ||
| Letter: Amines, anticonvulsants, and epilepsy | Q66701303 | ||
| Plasma protein binding of carbamazepine | Q66918773 | ||
| Flow-Dependent Salivary Primidone Levels in Epileptic Children | Q66923351 | ||
| Decreased serum 24,25-dihydroxy vitamin D concentrations in children receiving chronic anticonvulsant therapy | Q66956225 | ||
| Anticonvulsant Level in Saliva, Serum, and Cerebrospinal Fluid | Q66956563 | ||
| Plasma anticonvulsant concentrations during pregnancy | Q67010508 | ||
| Plasma Drug Level Monitoring in Pregnancy | Q67041229 | ||
| The pharmacokinetics of carbamazepine | Q67052582 | ||
| The clinical pharmacokinetics of phenytoin | Q67053866 | ||
| Interaction between carbamazepine and propoxyphene in man | Q67062825 | ||
| Inhibition of drug metabolism by chloramphenicol | Q67211676 | ||
| Trimethadione and human teratogenesis | Q67262200 | ||
| [The effect of hydantoin and succinimide on vitamin B 6 metabolism] | Q67267329 | ||
| Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva | Q67274955 | ||
| Effect of Antiepileptic Drugs on Serum and Salivary IgA | Q67332082 | ||
| Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay | Q67353832 | ||
| The bioavailability of carbamazepine | Q67369698 | ||
| Diphenylhydantoin, Phenobarbital, and Primidone in Saliva, Plasma, and Cerebrospinal Fluid | Q67380294 | ||
| Paradoxical Intoxication,:A Complication of Anticonvulsant Administration | Q67380298 | ||
| Distribution and elimination kinetics of carbamazepine in man | Q67396517 | ||
| Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses | Q67396551 | ||
| Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients | Q67396592 | ||
| Drug-Induced IgA Deficiency in Epileptic Patients | Q67442398 | ||
| Phenytoin: Pharmacokinetics and bioavailability | Q67443828 | ||
| Pharmacokinetic Model to Describe Self‐Induced Decreases in Steady‐State Concentrations of Carbamazepine | Q67445131 | ||
| A comparison of the absorption of phenobarbitone given via the oral and the intramuscular route | Q67459965 | ||
| Thickening of the heel-pad associated with long-term Dilantin therapy | Q67510234 | ||
| Isoniazid as an inhibitor of primidone metabolism | Q67514754 | ||
| Studies on the concentrations of chloramphenicol in the serum and cerebrospinal fluid of neonates, infants, and small children. Reciprocal reactions between chloramphenicol, penicillin and phenobarbitone | Q67541138 | ||
| Excretion of Valproic Acid into Semen of Rabbits and Man | Q40991325 | ||
| Effect of Anticonvulsants on Spiking Activity Induced by Cortical Freezing in Cats | Q41004943 | ||
| Valproic Acid Binding to Human Serum Albumin and Determination of Free Fraction in the Presence of Anticonvulsants and Free Fatty Acids | Q41004959 | ||
| Acute Hepatic Failure Associated with the Use of Sodium Valproate | Q41024278 | ||
| The effect of diphenylhydantoin, diazepam and clonazepam on the activity of Purkinje cells in the rat cerebellum | Q41063601 | ||
| Reye-like syndrome associated with valproic acid therapy | Q41098265 | ||
| Carbamazepine intoxication caused by interaction with isoniazid. | Q41112491 | ||
| Effects of antiepileptic drugs on thalamocortical excitability | Q41342850 | ||
| Sodium valproate in the treatment of intractable seizure disorders: A clinical and electroencephalographic study | Q41358363 | ||
| Factors influencing plasma concentrations of ethosuximide | Q41443333 | ||
| Antiepileptic drugs: metabolism in pregnancy | Q41443340 | ||
| Epilepsy Among Parents of Children with Facial Clefts | Q41445113 | ||
| Phosphorylation of the membrane-bound acetylcholine receptor: Inhibition by diphenylhydantoin | Q41477940 | ||
| A comparative study of the protein binding of anticonvulsant drugs in serum of dog and man | Q41506601 | ||
| Valproate-induced hepatic injury: analyses of 23 fatal cases | Q41602314 | ||
| Effect of Calcium and Antacids on Phenytoin Bioavailability | Q41667139 | ||
| Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: A kinetic approach | Q41677095 | ||
| Pharmacokinetics of Phenobarbital Following Single and Repeated Doses | Q41740591 | ||
| Phenytoin cumulation kinetics | Q41854366 | ||
| Diazepam absorption: effect of antacids and food | Q41888961 | ||
| The treatment of childhood epilepsy with sodium valproate | Q41896934 | ||
| Pharmacokinetics of valproic acid in young and elderly subjects | Q42089592 | ||
| Do anticonvulsants have a teratogenic effect? | Q42232913 | ||
| Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients | Q42239557 | ||
| Hyperglycemic, nonketotic coma following administration of Dilantin (Diphenylhydantoin). | Q42239695 | ||
| Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate | Q42239819 | ||
| Phenytoin (Dilantin) intoxication | Q42240232 | ||
| Asterixis associated with sodium valproate | Q42257339 | ||
| Stuporous episodes during treatment with sodium valproate: report of seven cases | Q42258113 | ||
| Pharmacokinetics of di-n-propylacetate in epileptic patients | Q42596442 | ||
| Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat | Q42596456 | ||
| Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration | Q42597665 | ||
| Interaction of phenytoin with chlorpheniramine [letter] | Q43241793 | ||
| Steady-state plasma nortriptyline concentrations in epileptic patients [letter] | Q43241905 | ||
| Interaction between phenytoin and imipramine | Q43253551 | ||
| Quantitation of phenobarbital and its main metabolites in human urine | Q43455187 | ||
| Reduced CSF IgG in patients treated with phenytoin (diphenylhydantoin) | Q43628262 | ||
| Morphine and phenytoin binding to plasma proteins in renal and hepatic failure | Q43713096 | ||
| Idiosyncratic reactions to the antiepileptic drugs | Q43719718 | ||
| Ceruloplasmin rise and PBI fall in serum due to diphenylhydantoin | Q43800491 | ||
| Effect of diphenylhydantoin on the metabolism of dexamethasone | Q43820962 | ||
| Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine | Q43846197 | ||
| Absorption and distribution of antiepileptic drugs | Q43869869 | ||
| Diphenylhydantoin concentrations in saliva | Q43972399 | ||
| Inhibition of diphenylhydantoin metabolism by chloramphenicol | Q43983201 | ||
| Drug interactions: effect of methylphenidate on the disposition of diphenylhydantoin in man. | Q44001501 | ||
| Effect of antiepileptic drugs on the elimination of various tetracycline derivatives | Q44288410 | ||
| Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin | Q44306123 | ||
| Plasma protein binding, plasma concentrations, and effects of diphenylhydantoin in man. | Q44354325 | ||
| Elevation of diphenylhydantoin and primidone serum concentration by addition of dipropylacetate, a new anticonvulsant drug | Q44416330 | ||
| The efficacy of carbamazepine combinations in epilepsy | Q44498076 | ||
| Interaction of chloramphenicol with phenytoin and phenobarbital. Case report | Q44653033 | ||
| Pharmacokinetics of single and multiple doses of phenytoin in man | Q44673846 | ||
| Preliminary observations on the pharmacokinetics of methylphenobarbitone | Q45059575 | ||
| Metabolism of ethosuximide | Q45119512 | ||
| Ethosuximide in the treatment of absence (peptit mal) seizures | Q45215486 | ||
| Incidence of diphenylhydantoin gingival hyperplasia | Q45251373 | ||
| Anticonvulsant osteomalacia determined by quantitative analysis of bone changes. Population study and possible risk factors | Q46281005 | ||
| Use of phenytoin serum levels in a case of status epilepticus | Q46337990 | ||
| The rate of decline of diphenylhydantoin in human plasma | Q46365064 | ||
| Effect of phenytoin on meperidine clearance and normeperidine formation | Q70971402 | ||
| Absorption and elimination of ethosuximide in children | Q70990035 | ||
| Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test | Q71040517 | ||
| A clinical study of serum primidone levels | Q71045931 | ||
| Interactions between digitoxin and other drugs in vitro and in vivo | Q71065191 | ||
| The clearance of anticonvulsant drugs in pregnancy | Q71120024 | ||
| Phenytoin intoxication during treatment with antabuse (Disulfiram) | Q71193658 | ||
| Effect of calcium and antacids on phenytoin bioavailability | Q71232120 | ||
| Effect of dose on phenytoin absorption | Q71295491 | ||
| Kinetics of a carbamazepine-ethosuximide interaction | Q71395561 | ||
| Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum | Q71395569 | ||
| Practical and theoretical aspects of phenytoin administration. I. Relationship between dose and plasma concentration | Q71397081 | ||
| Phenobarbital--valporic acid interaction | Q71494424 | ||
| Pancreatitis associated with valproic acid therapy for epilepsy | Q71496427 | ||
| Serum of concentrations of immunoglobulins in patients with epilepsy treated with carbamazepine | Q71502905 | ||
| Primidone kinetics: effects of concurrent drugs and duration of therapy | Q71509210 | ||
| Diphenylhydantoin and primidone in tears | Q71511172 | ||
| Valproic acid dosage and plasma protein binding and clearance | Q71514895 | ||
| Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects | Q71523457 | ||
| Disappearance of phenobarbital and diphenylhydantoin from serum of children | Q71533423 | ||
| Mechanism of valproate-phenobarbital interaction in epileptic patients | Q71537576 | ||
| Monotherapy or polytherapy for epilepsy? | Q71537832 | ||
| Protein binding of valproic acid in the presence of elevated free fatty acids in patient and normal human serum | Q71537837 | ||
| Concentration of metabolites of valproic acid in plasma of epileptic patients | Q71537861 | ||
| Human brain, plasma, and cerebrospinal fluid concentration of sodium valproate after 72 hours of therapy | Q71543340 | ||
| Anticonvulsant activity of metabolites of valproic acid | Q71545222 | ||
| Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy | Q71552394 | ||
| Hyperammonemia with valproic acid therapy | Q71558786 | ||
| Reduction of steady-state valproate levels by other antiepileptic drugs | Q71562582 | ||
| Outbreak of Anticonvulsant Intoxication in an Australian City | Q71582815 | ||
| Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects | Q71600930 | ||
| The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers | Q71601113 | ||
| Sodium valproate in the induction of unusual hepatotoxicity | Q71619324 | ||
| Use of stable labelled carbamazepine to study its kinetics during chronic carbamazepine treatment | Q71634302 | ||
| The Influence of Folic Acid on Phenytoin (DPH) Metabolism and the 24-Hours Fluctuation in Urinary Output of 5-(p-hydroxyphenyl)-5 phenyl-hydantoin (HPPH) | Q71739639 | ||
| Diphenylhydantoin: Placental transport, fetallocalization, neonatal metabolism, and possible teratogenic effects | Q71748588 | ||
| Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man | Q71817059 | ||
| Intravenous diphenylhydantoin in experimental seizures. II. Effect on penicillin-induced seizures in the cat | Q72040993 | ||
| Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures | Q72124403 | ||
| Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients | Q72124686 | ||
| Comparison of blood levels with oral and intramuscular diphenylhydantoin | Q72137960 | ||
| Disulfiramum (antabuse) as inhibitor of phenytoin metabolism | Q72189817 | ||
| Metabolic disposition of diphenylhydantoin in normal human subiects following intravenous administration | Q72409480 | ||
| Fatal hepatotoxicity in child on phenobarbitone and sodium valproate | Q72422655 | ||
| Decreased serum protein binding of phenytoin in late pregnancy | Q72428920 | ||
| Changes in Regional Brain Levels of Amino Acid Putative Neurotransmitters After Prolonged Treatment with t he Anticonvulsant Drugs Diphenylhydantoin, Phenobarbitone, Sodium Valproate, Ethosuximide, and Sulthiame in the Rat | Q72450245 | ||
| The influence of phenobarbital on the half-life of diphenylhydantoin in man | Q72453869 | ||
| Salivary levels of anticonvulsants: A practical approach to drug monitoring | Q39145895 | ||
| Excretion of antiepileptic drugs in sweat | Q39220508 | ||
| The effects of phenytoin on phenobarbitone and primidone metabolism | Q39246208 | ||
| Metabolic fate of phenobarbital in man. N-Glucoside formation | Q39281125 | ||
| Plasma binding of benzodiazepines in humans | Q39288625 | ||
| Phenytoin intoxication during concurrent diazepam therapy | Q39322301 | ||
| Digital hypoplasia and anticonvulsants during pregnancy | Q39322541 | ||
| Interactions of Antiepileptic Drugs | Q39336953 | ||
| Letter: Association between maternal intake of diazepam and oral clefts | Q39343232 | ||
| Letter: Carbamazepine and mother's milk | Q39343763 | ||
| Letter: Diazepam and plasma-testosterone levels | Q39343945 | ||
| Letter: Pyridoxine and serum concentration of phenytoin and phenobarbitone | Q39367386 | ||
| Anticonvulsants and parental epilepsy in the development of birth defects | Q39367479 | ||
| Therapeutic and pharmacokinetic effects of increasing phenytoin in chronic epileptics on multiple drug therapy | Q39467929 | ||
| Pharmacokinetics of drugs used for petit mal 'absence' epilepsy | Q39620278 | ||
| Ethosuximide Pharmacokinetics in a Pregnant Patient and Her Newborn | Q39644374 | ||
| Identification of Metabolites of Valproic Acid in Serum of Humans, Dog, Rat, and Mouse | Q39644385 | ||
| Which Anticonvulsant Drug? | Q39670675 | ||
| Pharmacological Interactions of Mesuximide with Phenobarbital and Phenytoin in Hospitalized Epileptic Patients | Q39670698 | ||
| Pancreatitis associated with valproic acid therapy | Q39690628 | ||
| Clinical Pharmacokinetics of Diazepam | Q39720641 | ||
| Clinical Pharmacokinetics of Phenytoin | Q39806205 | ||
| Biochemical and genetic factors regulating dilantin metabolism in man. | Q39866492 | ||
| Anticonvulsant drugs. II. Clinical pharmacological and therapeutic aspects. | Q39956570 | ||
| Pharmacokinetics of Carbamazepine in Man | Q40061423 | ||
| Phenytoin hepatotoxicity: a case report and review | Q40065194 | ||
| Electrophysiological actions of benzodiazepines | Q40121993 | ||
| Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review | Q40125639 | ||
| Clinical pharmacokinetics of valproic acid | Q40257001 | ||
| Use of antiepileptic drugs in the presence of liver and kidney diseases: a review | Q40266496 | ||
| Drug interactions with valproic acid | Q40267248 | ||
| Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. | Q40304319 | ||
| Antiepileptic drugs: pharmacokinetic and clinical aspects. | Q40306490 | ||
| Clinical pharmacokinetics of nitrazepam | Q40325640 | ||
| Pharmacokinetic interactions with antiepileptic drugs | Q40329711 | ||
| Clinical pharmacokinetics of anticonvulsants | Q40640508 | ||
| Use of saliva in therapeutic drug monitoring | Q40744854 | ||
| Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease | Q40755891 | ||
| Pharmacokinetics and bioavailability of sodium valproate | Q40771960 | ||
| Valproate sodium: a controlled clinical trial including monitoring of drug levels | Q40780318 | ||
| Disposition of valproic acid in man | Q40828077 | ||
| Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse | Q40849017 | ||
| Clinical Pharmacokinetics of Carbamazepine | Q40877361 | ||
| Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease | Q40897047 | ||
| Rectal administration of sodium valproate in status epilepticus | Q40936859 | ||
| Sodium Valproate Increases Potassium Conductance in Aplysia Neurons | Q40943508 | ||
| Plasma concentration of diazepam and N-desmethyldiazepam in children after a single rectal or intramuscular dose of diazepam | Q40977564 | ||
| Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses | Q46384348 | ||
| Diphenylhydantoin elimination kinetics in overdosed children | Q46920136 | ||
| Lymphocytic Thyroiditis Possibly Induced by Diphenylhydantoin | Q47784423 | ||
| Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital | Q47853247 | ||
| Serum Copper Levels and Diphenylhydantoin | Q47885399 | ||
| Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease | Q47886443 | ||
| Effect of phenobarbital on hyperlipemia in patients with intrahepatic and extrahepatic cholestasis | Q47987421 | ||
| Coagulation defects caused by diphenylhydantoin | Q48026089 | ||
| Unit activity of amygdala and hippocampal neurons: effects of morphine and benzodiazepines | Q48292670 | ||
| The mechanism of action of diphenylhydantoin or invertebrate neurons. I. Effects on basic membrane properties | Q48316952 | ||
| Brain concentrations of phenytoin, phenobarbitone and primidone in epileptic patients | Q48435790 | ||
| Facial clefts among epileptic patients | Q48664838 | ||
| Further observations on the interactions between phenobarbital and diphenylhydantoin during chronic treatment in the rat. | Q48794232 | ||
| Species difference in diazepam metabolism and anticonvulsant effect | Q49129886 | ||
| Water intoxication due to carbamazepine | Q49201789 | ||
| Kinetics of phenobarbital in normal subjects and epileptic patients | Q50124195 | ||
| Interaction of phenytoin and primidone | Q50321162 | ||
| Induction of sex hormone binding globulin by phenytoin | Q50328328 | ||
| Effects of trimethadione, diphenylhydantoin and chlordiazepoxide on after-discharges in brain of cat. | Q51287177 | ||
| Brain 5-hydroxytryptamine and anticonvulsant activity. | Q51295339 | ||
| The renal origin of sodium valproate-induced hyperammonemia in fasting humans. | Q51645961 | ||
| Effect of Diphenylhydantoin on Insulin Secretion in Man | Q51680621 | ||
| Barbiturates: active form and site of action at node of Ranvier sodium channels. | Q51867123 | ||
| Serum protein binding of drugs during and after pregnancy in humans. | Q51875039 | ||
| Diazepam disposition determinants. | Q51877437 | ||
| Induction Effect of Diazepam on its Own Metabolism | Q52113656 | ||
| Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation | Q52439737 | ||
| Pharmacological implications of microsomal enzyme induction. | Q52474261 | ||
| Diazepam concentrations in parotid saliva, mixed saliva, and plasma | Q52704364 | ||
| Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules | Q52707594 | ||
| Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects | Q52708114 | ||
| Plasma protein binding of diazepam and tolbutamide in chronic alcoholics. | Q52712237 | ||
| Letter: Association between maternal intake of diazepam and oral clefts. | Q52714787 | ||
| Clinical applications of gas chromatograph/mass spectrometer/computer systems | Q52716391 | ||
| Diazepam metabolism in normal man. I. Serum concentrations and clinical effects after intravenous, intramuscular, and oral administration. | Q52722036 | ||
| Letter: Concentrations of diazepam in adipose tissue of children. | Q52725352 | ||
| Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. | Q52727393 | ||
| The effect of certain drugs on the plasma protein binding of phenytoin. | Q52728947 | ||
| Diazepam and breast-feeding. | Q52734101 | ||
| Interaction between phenytoin and the benzodiazepines | Q52739204 | ||
| Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations | Q67541167 | ||
| Acetazolamide-induced interference with primidone absorption. Case reports and metabolic studies | Q67546732 | ||
| Carbamazepine and its 10,11-epoxide in children and adults with epilepsy | Q67549281 | ||
| Kinetics of primidone metabolism and excretion in children | Q67599335 | ||
| The influences of phenytoin on the fundamental electrical properties of simple neural systems | Q67653587 | ||
| Pharmacokinetics of nitrazepam in young volunteers and aged patients [proceedings] | Q67691177 | ||
| Effectiveness of prednisolone during phenytoin therapy | Q67711046 | ||
| Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy | Q67826136 | ||
| Immunoglobulin abnormalities in epileptic patients treated with diphenylhydantoin | Q67826415 | ||
| The elimination of phenytoin in man | Q67832201 | ||
| Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy | Q68266365 | ||
| The effects of phenobarbitone dose on plasma phenobarbitone levels in epileptic patients | Q68275108 | ||
| Characterization of the binding of benzodiazepines to human serum albumin | Q68522466 | ||
| [On resorption and distribution of methyl-ethyl-succinimide (MES) in serum and cerebrospinal fluid in children] | Q68577042 | ||
| Drug--interaction between sulthiame (Ospolot (R)) and phenytoin in the treatment of epilepsy | Q68742729 | ||
| Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution | Q68749158 | ||
| Pulmonary function loss in diphenylhydantoin therapy | Q68819488 | ||
| Metabolism of branched medium chain length fatty acid. I. Omega-oxidation of sodium dipropylacetate in rats | Q68856021 | ||
| Preliminary observations on the clinical pharmacology of carbamazepine ('Tegretol') | Q68920165 | ||
| Effects of Age, Sex, Obesity, and Pregnancy on Plasma Diphenylhydantoin Levels | Q68926969 | ||
| Studies on plasma protein binding of carbamazepine | Q68929708 | ||
| The concentration of carbamazepine (Tegretol R) in serum and in cerebrospinal fluid in patients with epilepsy | Q69022255 | ||
| Experiences with Bivotril in treatment of epilepsy--particularly minor motor epilepsy--in mentally retarded children | Q69033138 | ||
| Anticonvulsant-induced antinuclear antibodiesand lupus-like disease in children | Q69218005 | ||
| Interaction between Doxycycline and some Antiepileptic Drugs | Q69351369 | ||
| Variation in Response to Anticonvulsants in a Group of Epileptic Patients | Q69375981 | ||
| Phenylethylmalonamide (PEMA). An important metabolite of primidone | Q69375985 | ||
| The absorption and excretion of ethosuximide | Q69572251 | ||
| Diphenylhydantoin-induced Gingival Hyperplasia: its Relationship to Dose and Serum Level | Q69575135 | ||
| Studies on the disposition of the anticonvulsant clonazepam in the organisms of rat, dog, and man | Q69586772 | ||
| The Teratological Effects of Anticonvulsants and the Effects on Pregnancy and Birth | Q69623751 | ||
| Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy | Q69646920 | ||
| Diphenylhydantoin dosage | Q69688052 | ||
| Pharmacokinetic profiles of clonazepam in dog and humans and of flunitrazepam in dog | Q69764577 | ||
| Subnormal serum folate due to anticonvulsive therapy. A double-blind study of the effect of folic acid treatment in patients with drug-induced subnormal serum folates | Q69894300 | ||
| Dicoumarol-induced diphenylhydantoin intoxication | Q70066287 | ||
| Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy | Q70086060 | ||
| Effect of anticonvulsant drugs on dicophane (D.D.T.) residues in man | Q70111648 | ||
| Ethosuximide in tears, saliva, and cerebrospinal fluid | Q70222467 | ||
| Age and phenytoin kinetics in adult epileptics | Q70283751 | ||
| Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid | Q70347852 | ||
| Factors involved in an outbreak of phenytoin intoxication | Q70428736 | ||
| Valproic acid in pregnancy--association with spina bifida: a preliminary report | Q70430290 | ||
| Electrophysiological effects of diphenylhydantoin and carbamazepine on the peripheral and central nervous system | Q70442508 | ||
| Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies | Q70470596 | ||
| Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction | Q70490780 | ||
| Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants | Q70560587 | ||
| Malignant lymphogranulomatosis and anticonvulsant therapy | Q70604543 | ||
| Folic acid deficiency in patients receiving anticonvulsant drugs | Q70621565 | ||
| Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults | Q70681355 | ||
| Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy | Q70744771 | ||
| Pharmacokinetics and bioavailability of methylphenobarbital in man | Q70778036 | ||
| Influence of phenobarbital treatment on cimetidine kinetics | Q70792982 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 328-363 | |
| P577 | publication date | 1984-04-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Anticonvulsant drugs. An update | |
| P478 | volume | 27 |
| Q39502944 | Antiepileptic drug toxicity: definition and mechanism of action |
| Q42686092 | Carbamazepine-induced drowsiness |
| Q38720361 | Decreased phenytoin levels in patients receiving chemotherapy |
| Q51063182 | Design, synthesis and evaluation of 5-substituted 1-H-tetrazoles as potent anticonvulsant agents. |
| Q41615135 | Drug management of hypertensive disorders of pregnancy |
| Q40589552 | Drug-induced bone disease. |
| Q43229323 | Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. |
| Q39754383 | Free drug concentration monitoring in clinical practice. Rationale and current status |
| Q39548978 | Guide to drug dosage in renal failure |
| Q36024842 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma |
| Q44239661 | N-, alpha-, and beta-Substituted 3-Aminopropionic acids: design, syntheses and antiseizure activities. |
| Q70992420 | Neither dosage nor serum levels of antiepileptic drugs are predictive for efficacy and adverse effects |
| Q43672688 | Synthesis of some 1-(2-naphthyl)-2-(imidazole-1-yl)ethanone oxime and oxime ether derivatives and their anticonvulsant and antimicrobial activities |
| Q39675361 | The risk-benefit ratio of anticonvulsant drugs |
Search more.